短期抗血管内皮生长因子治疗会引发肿瘤血管生成拟态的形成，从而加速转移。
Short-term anti-vascular endothelial growth factor treatment elicits vasculogenic mimicry formation of tumors to accelerate metastasis.
机构信息
Department of Pharmacy, Shanghai First People's Hospital, School of medicine, Shanghai Jiao Tong University, No,100 Haining Road, Shanghai, 200080, China.
出版信息
J Exp Clin Cancer Res. 2012 Feb 23;31(1):16. doi: 10.1186/1756-9966-31-16.
BACKGROUND
Antiangiogenic therapy is one of the most significant advances in anticancer treatment. The benefits of antiangiogenic therapies of late-stage cancers have been investigated but are still too limited.
METHODS
We used an ovarian cancer model to test the effect of short-term bevacizumab treatment on metastasis as measured by bioluminescence. Western blotting and CD34-PAS dual staining were performed to assess hypoxia-inducible transcription factor-1α (HIF-1α) expression and vasculogenic mimicry(VM) formation. Cell viability was examined by a CCK8 assay.
RESULTS
Bevacizumab demonstrated antitumor effects in models of ovarian cancer, but also accelerated metastasis together, with marked hypoxia and VM formation in mice receiving short-term therapy. Bevacizumab treatment did not affect SKOV3 cell viability and the amount of VM in three-dimensional culture.
CONCLUSION
These results suggest that antiangiogenic therapy may potentially influence the progression of metastatic disease, which has been linked to the hypoxic response and VM formation.
背景
抗血管生成治疗是癌症治疗中最重要的进展之一。晚期癌症的抗血管生成治疗的益处已经得到了研究，但仍然非常有限。
方法
我们使用卵巢癌模型，通过生物发光来测试短期贝伐珠单抗治疗对转移的影响。通过 Western blot 和 CD34-PAS 双重染色来评估缺氧诱导因子-1α（HIF-1α）的表达和血管生成拟态（VM）的形成。通过 CCK8 测定法来检测细胞活力。
结果
贝伐珠单抗在卵巢癌模型中表现出抗肿瘤作用，但也加速了转移，接受短期治疗的小鼠出现明显的缺氧和 VM 形成。贝伐珠单抗治疗并不影响 SKOV3 细胞在三维培养中的活力和 VM 的数量。
结论
这些结果表明，抗血管生成治疗可能会影响转移性疾病的进展，这与缺氧反应和 VM 形成有关。
Zotero 插件